NCT07033897 (HARP3) is a NA clinical trial of Adapted HARP in Disabilities Physical, sponsored by Washington University School of Medicine.

Who is sponsoring NCT07033897?

NCT07033897 is sponsored by Washington University School of Medicine.

What drugs are being tested in NCT07033897?

Interventions in NCT07033897: Adapted HARP.

What condition does NCT07033897 study?

NCT07033897 studies Disabilities Physical, Falls, Fall Prevention, Adults.

Is NCT07033897 still recruiting?

NCT07033897 is currently recruiting now. Last updated 14 November 2025.

Last reviewed 2025-11-14 · How we verify

NCT07033897: HARP3

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adapting, Implementing and Evaluating the Effectiveness of HARP for People With Disabilities

Recruiting now NA Last updated 14 November 2025

What this trial tests

NA trial testing Adapted HARP in Disabilities Physical in 80 participants. Currently enrolling.

Timeline

20 August 2025

Primary endpoint
14 March 2028

14 March 2028

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	80
Start date	20 August 2025
Primary completion	14 March 2028
Estimated completion	14 March 2028
Sites	1 location across United States

Drugs / interventions tested

Adapted HARP

Conditions studied

Disabilities Physical — all drugs for Disabilities Physical →
Falls — all drugs for Falls →
Fall Prevention — all drugs for Fall Prevention →
Adults — all drugs for Adults →

Sponsor

Washington University School of Medicine

Who can join

Adults 45 to 64, any sex, with Disabilities Physical or Falls. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Home Hazard Removal Program (HARP) is an effective fall prevention intervention program which targets home hazard identification/removal. In this study the investigators will examine the effectiveness and implementation potential of HARP, adapted for PwD. Investigators will conduct a pilot randomized control trial (RCT) to test the implementation, cost, and preliminary efficacy of an adapted version of HARP for community-dwelling PwD. The single-blinded feasibility RCT will randomize 40 participants to treatment (adapted HARP) and 40 to a waitlist control group. Data on specific types of fall hazards and resulting home modifications as well as falls and fall-related injuries (collected monthly over 12 months) and fear of falling (collected at baseline and 12 months) will inform the preliminary efficacy of adapted HARP among PwD. To ensure usefulness, relevance, and broad dissemination of findings, the investigators will adopt a "designing for implementation and dissemination" approach. The RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework will guide intervention adaptation, trial design, and future implementation. The Practical Robust Implementation and Sustainability Model (PRISM) guides study development by identifying multi-level contextual factors hypothesized to affect the RE-AIM outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07033897 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 14 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07033897.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing